Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

180
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
180
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.9K
Destabilization of Microtubules01:45

Destabilization of Microtubules

2.7K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery and Mechanism of Action of a Novel Desloratadine Derivative Inhibiting <i>Mycobacterium tuberculosis</i> 3-Dehydroquinate Synthase.

Journal of chemical information and modeling·2026
Same author

Clickable Substrate Transport (CST): A High-Throughput Functional Assay for Solute Carrier Proteins.

ACS chemical biology·2026
Same author

Mechanisms of Resistance, Insights From Case Reports, and Future Prospects in Mycobacteriophage Therapy.

Journal of the Royal Society of New Zealand·2026
Same author

Synthesis of β-fluoropyrrolidines designed to reduce hERG affinity in a class of antiparasitic compounds.

ChemistrySelect·2026
Same author

Functional importance of Asp264 in the ketosynthase domain of Pks13 in <i>Mycobacterium smegmatis</i>.

Cell surface (Amsterdam, Netherlands)·2026
Same author

Hsa_circ_0003258 drives serine biosynthesis and docetaxel resistance in prostate cancer by enhancing IGF2BP3-mediated PSAT1 mRNA stability.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026

Related Experiment Video

Updated: Jul 4, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.6K

Azetidines Kill Multidrug-Resistant Mycobacterium tuberculosis without Detectable Resistance by Blocking Mycolate

Yixin Cui1, Alice Lanne2, Xudan Peng3

  • 1School of Chemistry, University of Birmingham, Edgbaston, Birmingham, West Midlands B15 2TT, U.K.

Journal of Medicinal Chemistry
|February 8, 2024
PubMed
Summary

New azetidine derivatives, BGAz, show potent bactericidal activity against drug-sensitive and multidrug-resistant tuberculosis (TB). These compounds target cell envelope biogenesis, offering a novel therapeutic approach for TB treatment.

More Related Videos

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

10.5K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.6K

Related Experiment Videos

Last Updated: Jul 4, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.6K
Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

10.5K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.6K

Area of Science:

  • Medicinal Chemistry
  • Microbiology
  • Drug Discovery

Background:

  • Tuberculosis (TB) remains a leading global infectious disease, causing significant morbidity and mortality.
  • The rise of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains necessitates the urgent development of novel anti-TB agents.
  • Existing treatments face challenges due to resistance and toxicity, highlighting the need for new drug targets and chemical scaffolds.

Purpose of the Study:

  • To identify novel chemical entities with potent activity against Mycobacterium tuberculosis.
  • To investigate the mechanism of action and drug resistance profile of newly identified compounds.
  • To evaluate the preclinical potential of these compounds as antitubercular chemotherapies.

Main Methods:

  • Whole-cell phenotypic screening of azetidine derivatives (BGAz) against Mycobacterium tuberculosis.
  • Determination of Minimum Inhibitory Concentration (MIC99) values for drug-sensitive and MDR-TB strains.
  • Mechanism of action studies including target deconvolution and transcriptomic analysis.
  • Assessment of toxicological and pharmacokinetic/pharmacodynamic (PK/PD) profiles.

Main Results:

  • A series of azetidine derivatives (BGAz) demonstrated potent bactericidal activity (MIC99 <10 μM) against both drug-sensitive and MDR-TB.
  • No detectable drug resistance was observed with the BGAz compounds.
  • Studies suggest BGAz compounds inhibit late-stage mycolic acid biosynthesis, a key component of the mycobacterial cell envelope.
  • Transcriptomic analysis revealed a distinct mode of action compared to existing cell wall inhibitors.
  • Promising toxicological and PK/PD profiles were observed, supporting further development.

Conclusions:

  • BGAz derivatives represent a novel class of compounds with significant potential for TB treatment.
  • Their unique mechanism of action targeting cell envelope biogenesis offers an advantage over existing therapies.
  • The favorable preclinical profiles suggest BGAz compounds are viable candidates for further antitubercular drug development.